Reply to Shirata et al

Clin Infect Dis. 2021 Oct 5;73(7):e1766-e1767. doi: 10.1093/cid/ciaa1923.

Takuji Komeda¹, Takahiro Takazono^{2

3}, Naoki Hosogaya^{2

4}, Eriko Ogura⁵, Hideyuki Miyauchi¹, Shinpei Iwata¹, Hiroshi Mukae^{2

6}

¹ PMS & Pharmacoepidemiology Department, Shionogi Pharmacovigilance Center Co., Ltd., Osaka, Japan.
² Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
³ Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
⁴ Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan.
⁵ Global Development Division, Shionogi & Co., Ltd., Osaka, Japan.
⁶ Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

No abstract available

Publication types